KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.66

-1.3%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.15M
EPS-2.8500
P/E Ratio-1.64
Earnings Date08/12/2026

klrs

Capital Lease Obligations

Last Annual Value

1.13M

3-Year CAGR

%

5-Year CAGR

-27%

10-Year CAGR

-15%

KT

Kalaris Therapeutics Inc Competitors Analysis of Capital Lease Obligations

KLRS · NASDAQ
CompanyCapital Lease Obligations
CAGR 3Y
CAGR 5Y
CAGR 10Y
1.13M
N/A-45.5%N/A 
13.42M
-5.7%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
34.63M
-8.2%13.2%N/A
91.70M
7.4%-1.9%N/A
0.00
N/AN/AN/A
25.96M
-3.1%82.4%N/A
736.00K
-16.6%-14.9%N/A
825.00K
10.6%N/AN/A
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.66, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.66